TABLE 3.
Treatment information
| Valuesa for: |
||
|---|---|---|
| Parameterb | Total cohort (n = 259) | Patients with MDR Pseudomonas aeruginosa (n = 226) |
| Infectious disease consult | 258 (99.6) | 226 (100.0) |
| Surgical consult | 62 (23.9) | 51 (22.6) |
| Source control in patients with infection amendable to source control | 59/80 (73.8) | 47/63 (74.6) |
| Active antibiotic(s) before C/T | 86 (34.4)c | 72 (31.9) |
| Time to active antibiotic(s) (h) | 50 (0–94)c | 54 (0–94) |
| Active antibiotic(s) within 48 h | 123 (49.2)c | 104 (46.0) |
| Time to C/T (h) | 85 (49–139) | 84 (51–127) |
| C/T within 48 h | 63 (24.3) | 51 (22.6) |
| C/T dose | ||
| High dose (3 g every 8 h) | 165 (63.7) | 143 (63.3) |
| Respiratory source | 116/163 (71.2) | 105/149 (70.5) |
| Standard dose (1.5 g every 8 h) | 94 (36.3) | 83 (36.7) |
| Renal dose adjustment | 79 (30.5) | 69 (30.5) |
| C/T IV combination therapy | 64 (24.7) | 58 (25.7) |
| Aminoglycoside | 47 (18.1) | 45 (19.9) |
| Colistin-polymyxin B | 11 (4.2) | 10 (4.4) |
| Fluoroquinolone | 10 (3.9) | 6 (2.7) |
| Inhaled antibiotic therapy in patients with a respiratory tract infectiond | 48/163 (29.4) | 44/149 (29.5) |
| C/T duration (days) | 10 (6–15) | 10 (6–15) |
a
All values represent number (%) or median (interquartile range).
b
C/T, ceftolozane-tazobactam; MDR, multidrug-resistant.
c
Evaluated in patients with a positive culture only, n = 250.
d
Inhaled tobramycin or colistin.